Publications

Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).

E Jordan, MA Lowery, W Wong, Y Kemel, S Mukherjee, V Ravichandran, ...

Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite …

FA Sinicrope, FS Ou, Q Shi, AB Nixon, K Mody, A Levasseur, AC Dueck, ...

Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype

MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ...

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in …

EM O'Reilly, V Sahai, JC Bendell, AJ Bullock, NK LoConte, H Hatoum, ...

Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial

AA Khorana, S Vadhan-Raj, NM Kuderer, T Wun, H Liebman, G Soff, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab‐paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O’Reilly, J Roach, P Miller, KH Yu, C Tjan, M Rosano, S Krause, ...

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

EM O'Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ...

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.

L Furchtgott, D Swanson, B Hayete, I Khalil, D Wuest, K Rich, AB Nixon, ...

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer

JJ Park, C Hajj, M Reyngold, W Shi, Z Zhang, JJ Cuaron, CH Crane, ...

Synthetic Lethality: Achilles Heel in Select Patient Subpopulations

MY Teo, EM O’Reilly

The evolving landscape of oncolytic virotherapy (OV) clinical trials (CT): Meta-analysis.

W Park, S Algaze, S Abi Aad, D Kwon, R Elias, N Acquavella, JR Merchan, ...

The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study

SH Olson, J Satagopan, Y Xu, L Ling, S Leong, I Orlow, A Saldia, P Li, ...

Treatment of pancreatic cancer by intra-arterial injection of an emulsion of Lipiodol and bumetanide (an anti-glycolytic drug) in a porcine model: initial results

H Yarmohammadi, AG Aguirre, L Schook, E Ziv, J Erinjeri, K Brown, ...

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux)+ capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure …

H Hurwitz, E Van Cutsem, JC Bendell, M Hidalgo, CP Li, M Garrido, ...

Understanding Pancreatic Cancer: National Pancreas Foundation's (NPF) Animated Pancreas Patient (APP): Informing Patients for Better Health Outcomes

S Munigala, E O'Reilly, M Alsante, J Holt, A Gelrud

Visceral thromboses (VT) in pancreas adenocarcinoma (PDAC): A systematic review.

A Mier Hicks, A Derosa, M Raj, RKG Do, KH Yu, MA Lowery, ...

A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).

AC Yang, A Wiesenthal, AS Epstein, J Zheng, J Goldberg, J Meadows, ...

A phase 2, open-label, multicenter study of durvalumab (MEDI4736)±tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.

EM O'Reilly, DY Oh, MA Lee, N Dhani, J Armstrong, R Belli, S Ferro, ...

Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive …

EM O’Reilly, TM Bauer, J Infante, JC Gutheil, P Klein, KH Yu, MA Lowery, ...

Abstract IA10: Biomarker selected therapy for pancreas ductal adenocarcinoma: an emerging reality?

EM O'Reilly

Adjuvant and neoadjuvant therapy for pancreatic cancer

D Li, EM O’Reilly

An atypical initial presentation of hepatocellular carcinoma as spinal cord compression

S Sangli, PK Mankal, E Fowle, J Abed, E O’Reilly, DP Kotler

APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected …

MA Tempero, DB Cardin, D Goldstein, EM O'Reilly, PA Philip, H Riess, ...

Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).

E Jordan, O Basturk, SD Leach, DS Klimstra, PJ Allen, MF Berger, ...

Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity.

KH Yu, M Ricigliano, EM O'Reilly, MA Lowery, B Cooper, CM Covington

Clinical and Molecular Analysis of Adenosquamous Carcinoma of the Pancreas

EJ Jordan, O Basturk, SD Leach, DS Klimstra, PJ Allen, MF Berger, ...

Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra-and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of …

MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, NE Kemeny, ...

Current management and future directions in metastatic pancreatic adenocarcinoma

AM Varghese, MA Lowery, KH Yu, EM O'Reilly

Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC)

AS Epstein, EM O’Reilly, E Shuk, W Breitbart, MA Shah, M Ly, R Tayler, ...

Discussions of life expectancy and changes in illness understanding in patients with advanced cancer

AS Epstein, HG Prigerson, EM O’Reilly, PK Maciejewski

Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?

IH Sahin, M Turkekul, M Capanu, G Askan, B McMahon, KH Yu, ...

Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma

EM O’Reilly

Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic …

M Ricigliano, B Cooper, AJ Ocean, H Tiriac, DA Tuveson, KH Yu, ...

Gemcitabine-related pneumonitis in pancreas adenocarcinoma—an infrequent event: elucidation of risk factors and management implications

IH Sahin, AI Geyer, DW Kelly, EM O'Reilly

Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine

ES Knudsen, EM O’Reilly, JR Brody, AK Witkiewicz

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches

IH Sahin, MA Lowery, ZK Stadler, E Salo-Mullen, CA Iacobuzio-Donahue, ...

Genomic landscape of pancreatic adenocarcinoma: Does age matter?

I Ben-Aharon, M Elkabets, R Pelossof, KH Yu, PJ Allen, ...

Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.

E Jordan, MA Lowery, R Ptashkin, A Zehir, MF Berger, H Maynard, ...

Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).

JJ Harding, ZJ Heins, LC Connell, T Soumerai, NE Kemeny, WR Jarnagin, ...

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …

AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ...

Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer

AK Witkiewicz, U Balaji, C Eslinger, E McMillan, W Conway, B Posner, ...

Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer

S Prasad, L Cambridge, F Huguet, JF Chou, Z Zhang, AJ Wu, EM O’Reilly, ...

Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

MY Teo, EM O’Reilly

Management of metastatic pancreatic adenocarcinoma

AR Cheema, EM O’Reilly

Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

DPS Sohal, PB Mangu, AA Khorana, MA Shah, PA Philip, EM O’Reilly, ...

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy

IH Sahin, CA Iacobuzio-Donahue, EM O’Reilly

Oxaliplatin neurotoxicity has a spectrum of manifestations from an often reversible acute neurotoxicity to a more irreversible “stocking and glove” chronic neuropathy that is …

IH Sahin, AI Geyer, DW Kelly, EM O'Reilly

Pancreas adenocarcinoma: ascites, clinical manifestations, and management implications

AM Hicks, J Chou, M Capanu, MA Lowery, KH Yu, EM O'Reilly

Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer

AD Rao, EA Sugar, DT Chang, KA Goodman, A Hacker-Prietz, LM Rosati, ...

Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).

MA Lowery, M Capanu, DC Glassman, CM Covington, J Gluskin, ...